Online Magazine Download now Europe Diplomatic Magazine

The European Commission has signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand name for Remdesivir. Veklury was the first medicine authorised at EU level for treatment of COVID-19. As from early August onwards, and in order to meet immediate needs, batches of Veklury will be made available to Member States and the UK, with the coordination and support of the Commission.

Stella Kyriakides, Commissioner for Health and Food Safety, said: “In recent weeks, the Commission has been working tirelessly with Gilead to reach an agreement to ensure that stocks of the first treatment authorised against COVID-19 are delivered to the EU. A contract has been signed yesterday, less than a month after the authorisation of Remdesivir, which will allow the delivery of treatments from early August for thousands of patients. The Commission is leaving no stone unturned in its efforts to secure access to safe and efficient treatments, and is supporting the development of vaccines against coronavirus. Yesterday’s agreement is another important step forward in our fight to overcome this disease”.

Stella Kyriakides © European Union

The Commission’s Emergency Support Instrument will finance the contract, worth a total of €63 million. This will ensure the treatment of approximately 30,000 patients presenting severe COVID-19 symptoms. This will help to cover the current needs over the next few months, while ensuring a fair distribution at EU level, based on an allocation key, taking into account the advice from the European Centre for Disease Prevention and Control.

The Commission is now also preparing a joint procurement for further supplies of the medicine, expected to cover additional needs and supplies as from October onwards.

Background

On 3 July, Remdesivir became the first treatment to be authorised for a conditional marketing authorisation. This authorisation facilitates early access to medicines in public health emergency situations, such as the current pandemic.

Remdesivir is a treatment against COVID-19 for adults and adolescents as from age 12 with pneumonia who require supplemental oxygen. The application for the marketing authorisation was submitted to the European Medicines Agency (EMA) on 8 June. EMA’s recommendation was endorsed by the Member States through the Standing Committee on Medicinal Products for Human Use.

While authorised in the EU, the medicine continues to be monitored to ensure safety. Gilead has also been requested to submit the final reports of the Remdesivir studies to the EMA by December 2020 as part of the conditions to be fulfilled to move from a conditional marketing authorisation to a full marketing authorisation. Further data on the effectiveness and safety of the medicine is expected to be submitted by August 2020 in order to finalise this process

Source: ec.europa.eu

Click here to read the 2020 August edition of Europe Diplomatic Magazine

Download 2020 August edition EuropeDiplomatic Magazine

More News

EUROPEAN REGION LOSES GROUND IN EFFORT TO ELIMINATE MEASLES

DOWN ON THE PHARM Raising drug prices is addictive

IAEA Director General Grossi Warns about Health Impact of Delayed Cancer Care During Pandemic

  • 5 mn
to

Latest news

RECEP TAYYIP ERDOGAN Turkey faces a new reality

  • 12 mn

LONELINESS BEGINS AT HOME – How a part of Russia came to be isolated and alone – but also good fun?

  • 13 mn

RED, GREEN AND IN BETWEEN :An old fashion industry maxim says “Red and Geeen Should Never Be Seen, but politician Daniel Cohn-Bendit exemplifies those clashing colours!

  • 12 mn

WHEN THE BOAT COMES IN? How Brexit is affecting the UK’s fishing industry

  • 12 mn

THE PLAYING FIELDS OF AFRICA – African nations with no UK connections queue up to join what was the British Commonwealth

  • 12 mn

OUT OF THE SHADOWS: New imaging method reveals concealed objects

  • 6 mn